Abstract: A method of operating a motorized flap arrangement of a motor vehicle, the flap arrangement including a flap, configured to be swiveled about a swivel axis, a drive arrangement, a drive controller, configured to control the drive arrangement, and a motion sensor arrangement, the sensor values determined by the motion sensor arrangement are checked for fulfillment of a specified actuation criterion, upon which an actuation effect manually exerted on the flap is deemed to be detected and the drive arrangement is controlled by the drive controller for motorized adjustment of the flap. The motion sensor arrangement arranged on a section of the flap facing away from the swivel axis. The actuation criterion is defined in such a way that the actuation criterion is fulfilled by a torque introduced into the flap before exceeding a breakaway torque of the flap kinematics.

Abstract: The present invention relates to designed ankyrin repeat domains having a reduced isoelectric point (pI) and/or having a reduced number of basic amino acid residues. The invention also provides such repeat domains linked to a drug moiety, for example a radionuclide or a cytotoxic agent. The invention furthermore provides methods for producing such repeat domains, as well as the use of such repeat domains in therapeutic and/or diagnostic methods. In addition, the invention provides recombinant proteins comprising such repeat domains, nucleic acids encoding such repeat domains or recombinant proteins, pharmaceutical compositions comprising such repeat domains, recombinant proteins nucleic acids, recombinant expression vectors and host cells, and the use of such proteins, nucleic acids or pharmaceutical compositions in methods for treating diseases, such as cancer.

Abstract: The present invention relates to designed ankyrin repeat domains having a reduced isoelectric point (pI) and/or having a reduced number of basic amino acid residues. The invention also provides such repeat domains linked to a drug moiety, for example a radionuclide or a cytotoxic agent. The invention furthermore provides methods for producing such repeat domains, as well as the use of such repeat domains in therapeutic and/or diagnostic methods. In addition, the invention provides recombinant proteins comprising such repeat domains, nucleic acids encoding such repeat domains or recombinant proteins, pharmaceutical compositions comprising such repeat domains, recombinant proteins nucleic acids, recombinant expression vectors and host cells, and the use of such proteins, nucleic acids or pharmaceutical compositions in methods for treating diseases, such as cancer.

Abstract: A door drive device for adjusting and/or locking a vehicle door relative to a vehicle body including an adjustment member, a drive element operatively coupled to the adjustment member such that the adjustment member is movable with respect to the drive element for moving the vehicle door, a sensor device for measuring a measuring quantity indicative of a movement of the vehicle door to provide a sensor signal, a brake device operatively connected to the drive element for braking a movement of the vehicle door, and a control device for controlling operation of the door drive device. The control device is configured to compute, from the sensor signal obtained from the sensor device, an acceleration value indicative of an acceleration of the vehicle door and evaluate the acceleration value to distinguish movement of the vehicle door caused by a gravity force from movement caused by a user action.

Abstract: An apparatus, methods, and a system for a photonic biosensor are disclosed. The photonic biosensor includes a substrate having a sample addition zone in fluid communication with a wicking zone and a sample detection zone. The substrate also includes an optical input port configured to optically couple to a light source and an optical output port configured to optically couple to a light detector. The photonic biosensor also includes a photonic integrated circuit (“PIC”) connected to the substrate. The PIC includes a first grating coupler aligned with the optical input port, a second grating coupler aligned with the optical output port, at least one waveguide between the first grating coupler and the second grating coupler, and at least one detection element disposed within the at least one waveguide.

Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.

Abstract: A door drive device for adjusting and/or locking a vehicle door relative to a vehicle body including an adjustment member, a drive element operatively coupled to the adjustment member such that the adjustment member is movable with respect to the drive element for moving the vehicle door, a sensor device for measuring a measuring quantity indicative of a movement of the vehicle door to provide a sensor signal, a brake device operatively connected to the drive element for braking a movement of the vehicle door, and a control device for controlling operation of the door drive device. The control device is configured to compute, from the sensor signal obtained from the sensor device, an acceleration value indicative of an acceleration of the vehicle door and evaluate the acceleration value to distinguish movement of the vehicle door caused by a gravity force from movement caused by a user action.

Abstract: The present invention is directed to a biosensor (10) having a photonic sensing device (20), a sheet of a porous material (60), and an optically clear cover layer (70). The optically clear cover layer (70) may be removable and replaceable, whereby the sheet of porous material (60) can be replaced, and the photonic sensing device (20) can be re-used. Detection devices (810, 910) that include the biosensor (10), as well as methods of making and using the biosensor (10) are also disclosed.

Abstract: Device for operating an electric motor, comprising a detection unit for detecting zero-crossings and phase angles of applied phase-shifted sinusoidal voltage phases of a multi-phase power supply network; and a switching unit for connecting half-waves of the applied sinusoidal voltage phases through by means of semiconductor switches in accordance with switching patterns applied to the semiconductor switches, said patterns being synchronised with the detected phase angles and zero-crossings, to generate phase-shifted quasi-sinusoidal voltage phases which are applied directly to the electric motor.

Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.

Abstract: Device for operating an electric motor, comprising a detection unit for detecting zero-crossings and phase angles of applied phase-shifted sinusoidal voltage phases of a multi-phase power supply network; and a switching unit for connecting half-waves of the applied sinusoidal voltage phases through by means of semiconductor switches in accordance with switching patterns applied to the semiconductor switches, said patterns being synchronised with the detected phase angles and zero-crossings, to generate phase-shifted quasi-sinusoidal voltage phases which are applied directly to the electric motor.

Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.

Abstract: New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin.

Abstract: Fuse load-break switch (1) for low-voltage high-power fuses, a fuse contact pair for receiving a fuse (5A, 5B, 5C) being provided within a housing (2) of the fuse load-break switch (1) for each current phase to be disconnected, characterized in that a thermal power loss brought about by the fuses (5A, 5B, 5C) is dissipated into at least one heat dissipation duct (3) provided laterally on the housing (2) of the fuse load-break switch (1).

Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.

Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.

Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.

Abstract: The present invention relates to a filamentous phage display method wherein the polypeptides of interest displayed on the phage particle are cotranslationally translocated across the cytoplasmic membrane of Gram-negative bacteria based on the signal recognition particle pathway. This method is particularly suitable for polypeptides, which are known to be difficult to display on phages, and for proteins of cDNA libraries and other combinatorial libraries, in particular when derived from very fast folding, stable protein scaffolds. The invention further relates to phage or phagemid vectors useful in the method comprising a gene construct coding for a fusion polypeptide comprising the polypeptide to be displayed on the phage particle and an N-terminal signal sequence promoting cotranslational translocation.

Abstract: New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin.

Abstract: New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin.